advancedstag
cancer
difficult
control
use
convent
therapi
chemotherapi
surgeri
radiat
therefor
new
innov
therapi
urgent
requir
order
combat
high
mortal
morbid
associ
cancer
antigenspecif
immunotherapi
emerg
attract
approach
treatment
cancer
sinc
abil
specif
erad
system
tumor
control
metastas
without
damag
normal
cell
dna
vaccin
becom
potenti
promis
approach
antigenspecif
immunotherapi
due
safeti
stabil
eas
prepar
review
see
previous
develop
sever
innov
strategi
enhanc
dna
vaccin
potenc
directli
target
dna
dendrit
cell
dc
vivo
via
gene
gun
well
modifi
properti
antigenexpress
dc
review
see
one
strategi
enhanc
dna
vaccin
potenc
use
intracellular
target
strategi
enhanc
major
histocompat
complex
mhc
class
antigen
present
process
dc
previous
studi
linkag
calreticulin
crt
protein
locat
endoplasm
reticulum
review
see
sever
antigen
includ
human
papilloma
viru
nucleocapsid
protein
sever
acut
respiratori
syndrom
coronaviru
intraderm
administr
crt
link
target
antigen
led
signific
increas
antigenspecif
cell
ctl
immun
respons
impress
antitumor
effect
thu
crt
shown
highli
potent
enhanc
antigenspecif
immun
respons
antitumor
effect
gener
dna
vaccin
sever
preclin
model
anoth
import
innov
cancer
therapi
involv
employ
proteasom
inhibitor
proteasom
play
import
role
number
cellular
process
may
contribut
cancer
cell
growth
surviv
suggest
proteasom
inhibitor
could
provid
new
promis
class
anticanc
agent
review
see
dipeptid
boron
acid
analog
bortezomib
also
known
inhibit
function
proteasom
first
proteasom
inhibitor
use
clinic
set
drug
food
drug
administr
approv
current
clinic
trial
treatment
multipl
myeloma
well
mani
other
hematolog
solid
tumor
includ
lymphoma
chronic
lymphocyt
leukemia
cancer
head
neck
prostat
breast
current
studi
hypothes
combin
dna
vaccin
encod
crt
link
proteasom
inhibitor
bortezomib
lead
enhanc
antitumor
effect
tumor
preclin
model
observ
combin
treatment
bortezomib
detox
dna
gener
potent
cell
immun
respons
signific
therapeut
effect
tumor
tumorbear
mice
furthermor
treatment
bortezomib
led
increas
apoptosi
tumor
cell
tumorbear
mice
addit
treatment
bortezomib
could
render
tumor
cell
suscept
lysi
ctl
vitro
clinic
implic
current
studi
discuss
six
femal
mice
purchas
nation
cancer
institut
frederick
md
usa
hous
oncolog
anim
facil
john
hopkin
hospit
baltimor
md
usa
anim
procedur
perform
accord
approv
protocol
accord
recommend
proper
use
care
laboratori
anim
previous
gener
tumorigen
cell
line
firefli
luciferaseexpress
cell
line
commerci
avail
bortezomib
millennium
pharmaceut
reconstitut
accord
manufactur
instruct
dilut
salin
vivo
administr
obtain
nation
institut
health
nation
gene
vector
laboratori
secondgener
plasmid
encod
kanamycinresist
gene
transcript
unit
consist
cytomegaloviru
promot
multipl
clone
site
follow
polya
tail
contain
two
short
immunostimulatori
dna
sequenc
iss
noncod
region
backbon
iss
sequenc
deriv
bacteri
ampicillinresist
gene
consist
tandem
repeat
cpg
dinucleotid
base
context
demonstr
isscontain
pdna
elicit
product
interferon
ifn
interleukin
transfect
keratocyt
dermal
antigenpres
cell
result
potent
helper
cell
type
respons
vector
also
contain
transcript
unit
yield
high
level
ag
express
dna
adjuv
unit
elicit
strong
immunolog
type
respons
pdnaencod
protein
oncogen
protein
detox
form
substitut
amino
acid
posit
glycin
place
cystein
glycin
place
glutam
acid
substitut
shown
inhibit
protein
bind
prb
posit
abat
abil
transform
cell
thu
adequ
use
clinic
trial
gene
gunmedi
intraderm
vaccin
dnacoat
gold
particl
dna
per
bullet
deliv
shave
abdomin
region
mice
use
heliumdriven
gene
gun
biorad
hercul
ca
usa
discharg
pressur
psi
accord
manufactur
protocol
mice
vaccin
via
gene
gun
two
bullet
total
dna
mice
receiv
two
booster
vaccin
regimen
interv
mice
inocul
subcutan
per
mous
cell
day
tumorbear
mice
divid
four
group
five
per
group
base
treatment
regimen
control
treatment
bortezomib
bortezomib
administr
bortezomib
mgkg
bortezomib
inject
intraperiton
day
tumor
inocul
gene
gun
administr
dna
inject
tumorbear
mice
day
tumor
inocul
immun
assay
done
differ
immun
respons
model
nontumor
model
mice
given
bortezomib
andor
dna
vaccin
describ
vivo
treatment
without
tumor
inocul
tumor
model
mice
inocul
tumor
cell
treat
treatment
describ
vivo
treatment
experi
splenocyt
harvest
differ
group
mice
day
last
vaccin
dna
prior
intracellular
cytokin
stain
per
mous
pool
splenocyt
vaccin
group
incub
h
peptid
contain
mhc
class
db
epitop
aa
detect
antigenspecif
cell
precursor
presenc
golgiplug
bd
pharmingen
san
diego
ca
usa
intracellular
stain
flow
cytometri
analysi
perform
describ
previous
analysi
perform
bectondickinson
facscan
cellquest
softwar
bectondickinson
immunocytometri
system
mountain
view
ca
usa
order
induc
apoptosi
control
bortezomibtr
cell
use
bortezomib
mgkg
intraperiton
inject
interv
start
tumor
model
cell
sc
challeng
mice
sacrif
h
last
bortezomib
dosag
tumor
cell
prepar
singl
cell
suspens
method
stain
phycoerythrin
pe
conjug
annexin
v
vital
dye
protocol
cell
acquir
analyz
facscan
cytometri
order
distinguish
three
differ
popul
protocol
stain
describ
follow
cell
resuspend
least
cell
per
millilit
tube
two
millilit
cold
phosphatebuff
salin
pb
ad
tube
centrifug
min
rpm
pellet
resuspend
ml
cold
pb
centrifug
min
rpm
cell
resuspend
ml
bind
buffer
use
sampl
ml
bind
buffer
ad
wash
one
hundr
microlit
incub
solut
peconjug
annexin
v
ad
tube
gentli
vortex
tube
incub
room
temperatur
min
dark
ml
bind
buffer
ad
centrifug
min
rpm
supernat
remov
four
hundr
microlit
bind
buffer
ad
sampl
sampl
analyz
within
h
stain
flow
cytometri
analysi
perform
bectondickinson
facscan
cellquest
softwar
bectondickinson
immunocytometri
system
mountain
view
ca
usa
vitro
cytotox
kill
assay
per
well
luciferaseexpress
cell
plate
plate
cell
treat
without
nm
bortezomib
overnight
h
use
target
cell
ctl
incub
target
cell
e
ratio
h
cell
previous
describ
target
cell
incub
without
ctl
serv
neg
control
luciferin
mg
per
well
ad
well
optic
imag
xenogen
ivi
tumor
size
monitor
measur
longest
dimens
length
shortest
dimens
width
interv
use
dial
calip
tumor
volum
calcul
follow
formula
tumor
diamet
length
width
mice
kill
time
experi
tumor
size
cm
longest
dimens
data
express
mean
standard
error
se
repres
least
two
independ
experi
comparison
individu
data
point
made
student
test
surviv
curv
tumor
treatment
experi
appli
determin
signific
differ
curv
p
valu
calcul
use
logrank
test
p
consid
signific
graph
plot
use
sigmaplot
program
file
systat
softwar
inc
determin
antitumor
effect
treatment
proteasom
inhibitor
bortezomib
combin
vaccin
dna
encod
crt
link
mutat
form
detox
first
challeng
group
mice
five
per
group
tumor
cell
treat
bortezomib
andor
dna
vaccin
illustr
fig
shown
fig
tumorbear
mice
treat
bortezomib
combin
detox
dna
show
significantli
lower
tumor
volum
time
compar
tumorbear
mice
treat
bortezomib
alon
dna
vaccin
alon
furthermor
tumorbear
mice
treat
bortezomib
combin
detox
dna
show
significantli
improv
surviv
compar
tumorbear
mice
treat
bortezomib
alon
dna
vaccin
alon
fig
thu
data
suggest
combin
treatment
use
bortezomib
detox
dna
gener
best
therapeut
antitumor
effect
longterm
surviv
tumorbear
mice
order
determin
cell
immun
respons
tumorbear
mice
treat
bortezomib
andor
detox
dna
first
challeng
group
mice
five
per
group
tumor
cell
treat
dna
vaccin
alon
bortezomib
alon
bortezomib
combin
dna
vaccin
illustr
fig
seven
day
last
treatment
harvest
splenocyt
vaccin
mice
character
presenc
cell
use
intracellular
cytokin
stain
follow
flow
cytometri
analysi
shown
fig
tumorbear
mice
administ
bortezomib
combin
detox
dna
gener
significantli
higher
number
cell
compar
tumorbear
mice
administ
detox
dna
alon
addit
treatment
bortezomib
alon
significantli
increas
number
cell
tumorbear
mice
compar
untreat
mice
data
shown
thu
result
suggest
treatment
tumorbear
mice
bortezomib
enhanc
cell
immun
respons
gener
detox
dna
vaccin
order
determin
whether
cell
immun
respons
mice
vaccin
detox
dna
enhanc
treatment
bortezomib
treat
mice
five
per
group
bortezomib
intraperiton
four
time
interv
seven
day
initi
administr
bortezomib
mice
vaccin
detox
dna
via
gene
gun
three
time
interv
illustr
fig
one
week
last
vaccin
harvest
splenocyt
vaccin
mice
character
presenc
cell
use
intracellular
cytokin
stain
follow
flow
cytometri
analysi
shown
fig
mice
treat
bortezomib
enhanc
cell
respons
gener
detox
dna
vaccin
graphic
represent
number
cell
depict
fig
thu
result
suggest
treatment
mice
bortezomib
lead
enhanc
cell
immun
respons
gener
detox
dna
vaccin
taken
togeth
data
suggest
treatment
bortezomib
enhanc
cell
respons
gener
detox
dna
vaccin
presenc
tumor
sinc
treatment
bortezomib
enhanc
cell
respons
gener
detox
dna
vaccin
presenc
tumor
reason
bortezomib
may
lead
increas
apoptosi
tumor
cell
lead
increas
number
cell
precursor
enhanc
immun
respons
thu
order
determin
treatment
bortezomib
lead
increas
apoptosi
tumor
cell
tumorbear
mice
first
challeng
mice
five
per
group
tumor
cell
subcutan
one
week
later
tumorbear
mice
treat
bortezomib
intraperiton
four
time
interv
twentyfour
hour
later
tumor
cell
treat
mice
harvest
stain
annexin
v
character
apoptosi
use
flow
cytometri
analysi
shown
fig
tumor
cell
isol
mice
treat
bortezomib
gener
significantli
higher
percentag
apoptot
tumor
cell
compar
tumor
cell
isol
untreat
mice
figur
demonstr
bar
graph
depict
percentag
apoptot
tumor
cell
tumor
cell
isol
mice
treat
without
bortezomib
result
suggest
treatment
tumorbear
mice
bortezomib
lead
signific
apoptosi
tumor
cell
order
determin
treatment
tumor
cell
bortezomib
render
tumor
cell
suscept
tcellmedi
kill
perform
cytotox
assay
use
luciferaseexpress
tumor
cell
tumor
cell
treat
bortezomib
without
ctl
untreat
tumor
cell
cell
treat
ctl
alon
use
control
ctlmediat
kill
tumor
cell
well
monitor
use
bioluminesc
imag
system
assay
use
previous
us
other
degre
ctlmediat
kill
tumor
cell
shown
correl
decreas
luminesc
activ
shown
fig
lowest
luciferas
activ
observ
well
incub
bortezomib
cytotox
cell
compar
well
incub
bortezomib
alon
cytotox
cell
alon
thu
data
suggest
tumor
cell
treat
bortezomib
increas
suscept
tumor
cell
lysi
cytotox
cell
also
observ
treatment
bortezomib
alon
led
higher
degre
tumor
cell
death
compar
ctl
alon
use
specifi
condit
vitro
studi
howev
observ
effect
may
depend
concentr
bortezomib
andor
number
ctl
use
vitro
kill
assay
also
perform
ctl
kill
assay
use
tumor
treat
differ
concentr
bortezomib
observ
cell
treat
increas
dose
bortezomib
demonstr
enhanc
ctlmediat
kill
supplementari
fig
thu
result
indic
tumor
cell
treat
increas
dose
bortezomib
increas
suscept
tumor
cell
lysi
cytotox
cell
current
studi
observ
combin
treatment
bortezomib
detox
dna
gener
potent
cell
immun
respons
result
signific
therapeut
effect
tumor
tumorbear
mice
furthermor
treatment
bortezomib
led
increas
apoptosi
tumor
cell
could
render
tumor
cell
suscept
lysi
ctl
thu
combin
treatment
bortezomib
detox
dna
repres
potenti
innov
therapi
control
tumor
select
antigen
dna
vaccin
develop
current
studi
clear
persist
infect
hpv
primari
factor
develop
cervic
cancer
hpv
one
common
sexual
transmit
diseas
world
hpv
dna
detect
cervic
cancer
furthermor
highrisk
type
associ
cervic
cancer
review
see
hpv
earli
viral
protein
potenti
ideal
target
antigen
sinc
complet
foreign
antigen
express
earli
viral
infect
furthermor
essenti
transform
coexpress
almost
hpvassoci
cancer
cell
normal
cell
thu
dna
vaccin
target
antigen
potenti
use
control
hpvassoci
malign
time
administr
bortezomib
potenti
import
enhanc
cell
immun
respons
gener
dna
vaccin
report
prolifer
cell
rest
cell
highli
sensit
bortezomibmedi
cytotox
current
studi
administ
bortezomib
second
dna
vaccin
would
increas
suscept
treat
tumor
without
compromis
cell
sinc
first
dna
vaccin
gener
result
signific
number
prolif
antigenspecif
cell
also
see
fig
thu
eventu
clinic
translat
import
determin
time
administr
bortezomib
order
gener
enhanc
therapeut
antitumor
effect
use
dna
vaccin
studi
observ
treatment
bortezomib
led
increas
apoptot
cell
death
tumor
cell
apoptot
tumor
cell
may
potenti
taken
antigenpres
cell
result
activ
tumorspecif
cell
call
crossprim
mechan
previous
observ
treatment
tumor
egcg
led
apoptot
tumor
cell
death
result
higher
level
peptideload
dendrit
cell
drain
lymph
node
tumorbear
mice
increas
level
peptideload
dendrit
cell
result
increas
number
cell
precursor
treat
mice
thu
treatment
egcg
significantli
boost
potenc
dna
vaccin
enhanc
cell
immun
respons
antitumor
effect
similarli
treatment
bortezomib
also
led
apoptot
tumor
cell
death
thu
enhanc
dna
vaccin
potenc
therefor
would
interest
observ
degre
apoptot
cell
death
gener
reagent
correl
abil
enhanc
dna
vaccin
potenc
observ
treatment
bortezomib
render
tumor
cell
suscept
kill
cell
sever
mechan
may
account
observ
phenomenon
exampl
bortezomib
may
lead
upregul
mhc
class
result
increas
recognit
antigen
class
complex
cell
howev
character
express
mhc
class
tumor
cell
follow
treatment
bortezomib
find
signific
chang
level
mhc
class
cell
data
shown
furthermor
report
tumor
cell
treat
bortezomib
lead
increas
express
mhc
class
molecul
altern
treatment
bortezomib
may
lead
increas
express
protein
andor
death
receptor
dr
shown
renal
cell
carcinoma
cell
treat
bortezomib
demonstr
upregul
furthermor
report
treatment
tumor
bortezomib
lead
upregul
molecul
may
sensit
tumor
apoptot
cell
death
fa
render
tumor
suscept
immun
cell
express
death
ligand
fasl
character
express
fasl
cell
found
cell
express
fasl
see
supplementari
fig
addit
cell
shown
express
fa
thu
data
indic
sensit
tumor
bortezomib
presum
upregul
fa
tumor
cell
may
contribut
enhanc
cytotox
kill
cell
would
interest
character
manipul
molecul
order
illustr
mechan
increas
suscept
tumor
kill
cell
summari
studi
demonstr
combin
treatment
bortezomib
detox
dna
gener
potent
cell
immun
respons
result
signific
therapeut
effect
tumor
tumorbear
mice
would
import
determin
optim
dose
regimen
bortezomib
dna
vaccin
order
gener
best
therapeut
effect
preclin
model
inform
would
serv
import
foundat
futur
clinic
translat
